title: The effects of anemia in hematologic malignancies: more than a symptom.
abstract: Anemia is a common complication in patients with hematologic malignancies, and is caused by a variety of mechanisms, including neoplastic cell infiltration into the bone marrow, hemolysis, nutritional deficiencies, and defects in erythropoiesis as a result of the disease itself or cytotoxic therapy. The anemia associated with multiple myeloma is caused by inadequate erythropoietin levels consequent to renal impairment and the effect of inflammatory cytokines. The degree of anemia can have prognostic importance, as is the case with multiple myeloma, or be a significant indicator of disease stage, as noted with chronic lymphocytic leukemia. Anemia results in fatigue, exhaustion, dizziness, headache, dyspnea, and decreased motivation, seriously affecting a patient's quality of life. Since anemia is so prevalent in hematologic malignancy patients, its treatment must be an integral part of disease management, to improve quality of life and to possibly increase potential survival. Clinical studies have shown that effectively treating anemia and increasing hemoglobin levels using recombinant human erythropoietin (rHuEPO, epoetin alfa) has a significant effect on transfusion requirements and quality of life.
authors.affiliation: Department of Haematology, John Radcliffe Hospital, Oxford, UK.
authors.forename: Timothy
authors.initials: T
authors.lastname: Littlewood
authors.forename: Franco
authors.initials: F
authors.lastname: Mandelli
mesh_terms: D000740:Anemia / Q000209:etiology* / Q000517:prevention & control*; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006397:Hematinics / Q000627:therapeutic use; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000150:complications*; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000150:complications*; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications*; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000150:complications*; D011379:Prognosis; D011788:Quality of Life; D011994:Recombinant Proteins; D015996:Survival Rate
chemical_list: D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D000068817:Epoetin Alfa